Sort
82,697 grants matching “vaccine development”
Herpes Simplex Immunotherapeutic Vaccine
$999,688Sean M. Sullivan · Vical, Inc. · R42 · FY2008 · AI
Immune Regulation in Mycobacterial and Fungal Infections
$999,676Daniel Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Development of an H2O2-inactivated chikungunya virus vaccine
$999,652Ian James Amanna · Najit Technologies, Inc. · R44 · FY2017 · AI
SOUTH AFRICA MRC HIV PREVENTION TRIALS UNIT
$999,652Medical Research Council Of South Africa · U01 · FY2000 · AI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine
$999,652Ian James Amanna · Najit Technologies, Inc. · U44 · FY2021 · AI
Drug Repurposing Screening for Zika Virus Infection
$999,652Wei Zheng · National Center For Advancing Translational Sciences · ZIA · FY2020 · TR
Conformational Stabilization of the HIV-1 Env Trimer
$999,646Christopher Marshall · Avatar Medical, Llc · R44 · FY2015 · AI
Conformational Stabilization of the HIV-1 Env Trimer
$999,641Christopher Marshall · Avatar Medical, Llc · R44 · FY2013 · AI
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
$999,604Elke Lipka · Tsrl, Inc. · R44 · FY2023 · AI
Immunity to Bacillus anthracis: Spore-Host Interactions
$999,589John Franklin Kearney · University Of Alabama At Birmingham · P01 · FY2006 · AI
Product optimization to commercialize an oral bacteriophage cocktail that prevents cholera in real-world settings
$999,585Minmin Yen · Phagepro, Inc. · R44 · FY2021 · AI
PfSPZ Vaccine for Malaria: Towards a Successful Biologics License Application and Commercialization
$999,570Stephen Lev Hoffman · Sanaria, Inc. · SB1 · FY2021 · AI
Induction of an Antitumor Immune Response in Patients with Melanoma
$999,555Patrick Hwu · University Of Tx Md Anderson Can Ctr · P50 · FY2011 · CA
Dendritic Cell-Targeted HIV Vaccine Product
$999,540Tibor Keler · Celldex Therapeutics, Inc. · R44 · FY2014 · AI
PIPP Phase I: Evaluating the Effectiveness of Messaging and Modeling during Pandemics (PandEval)
$999,537Louiqa Raschid · University Of Maryland, College Park · · FY2022 · SBE
Strain-Independent Therapeutic Antibodies for Influenza
$999,451Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2021 · AI
Development and Experimental Verification of Fundamental Models to Enable Implementation of Microwave-Assisted Freeze Drying
$999,448Emily S Gong · Physical Sciences, Inc · U01 · FY2022 · FD
Coordinate Regulation of Virulence in Vibrio Cholerae
$999,436John J Mekalanos · Harvard Medical School · R37 · FY2025 · AI
Colorado AMC REACH Hub
$999,434Richard C Duke · University Of Colorado Denver · U01 · FY2019 · HL
Core D: Clinical Research Core
$999,419Ighovwerha Ofotokun · Emory University · P30 · FY2019 · AI
Lymphocyte Dynamics
$999,413William Paul · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?
$999,410David I Watkins · Mabloc, Llc · R42 · FY2021 · AI
Miami Pediatric AIDS Clinical Trials Unit
$999,382University Of Miami School Of Medicine · U01 · FY2005 · AI
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$999,369Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
$999,369Lijun Rong · Chicago Biosolutions, Inc. · R42 · FY2022 · AI